Prostate Cancer

>

Latest News

Overall urinary toxicity was not significantly improved with SBRT vs moderately hypofractionated IMRT.
SBRT Reduces Bowel Toxicity vs IMRT in Intermediate-Risk Prostate Cancer

September 30th 2025

SBRT achieved a 5-year DFS of 89% vs 92% with moderately hypofractionated IMRT in patients with intermediate risk prostate cancer.

While metastasis-directed therapy has shown it may be a tool for prolonging PFS in other research, progression does still occur in most patients.
Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate Cancer

September 29th 2025

Apalutamide plus stereotactic radiotherapy may be effective for certain patients with recurrent prostate cancer following radical prostatectomy.
PAM50 Biomarker May Predict Apalutamide Efficacy in Prostate Cancer

September 29th 2025

Carotuximab/Apalutamide Improves PFS in Previously Treated Metastatic CRPC
Carotuximab/Apalutamide Improves PFS in Previously Treated Metastatic CRPC

September 24th 2025

FDA OKs Leuprolide Mesylate 3-Month Formulation in Advanced Prostate Cancer
FDA OKs Leuprolide Mesylate 3-Month Formulation in Advanced Prostate Cancer

August 29th 2025

Video Series
Video Interviews
Podcasts
1 expert in this video
1 expert in this video
1 expert in this video
AI tools may show utility in areas such as prostate diagnostic imaging, pathology, and treatment outcome predictions.
Latest CME Events & Activities

More News